Capricor Therapeutics

Capricor Therapeutics

Yahoo Finance • yesterday

Capricor outlines 2027 manufacturing validation as Deramiocel BLA heads toward Nov. 22 PDUFA date

Earnings Call Insights: Capricor Therapeutics (CAPR) Q3 2026 MANAGEMENT VIEW * “Our BLA for Deramiocel is in the final stages of FDA review,” and “FDA then agreed to review additional data in a major amendment to our BLA and extended t... Full story

Yahoo Finance • last month

Capricor drops as deramiocel OLE data fails to quell regulatory concerns

[Stock chart going down.] Capricor Therapeutics (CAPR [https://seekingalpha.com/symbol/CAPR]) is down ~10% in Monday trading despite releasing positive data from an open-label extension study for deramiocel for Duchenne muscular dystrophy... Full story

Yahoo Finance • last month

Capricor jumps as study shows longer-term effects of deramiocel

[Duchenne muscular dystrophy genetic test] Hailshadow/iStock via Getty Images Capricor Therapeutics (CAPR [https://seekingalpha.com/symbol/CAPR]) shares surged in late trading Tuesday as investors reacted to new data on deramiocel, the bi... Full story

Yahoo Finance • 2 months ago

Sector Update: Healthcare Stocks Gain Late Afternoon

Healthcare stocks advanced late Monday afternoon, with the NYSE Healthcare Index up 1.5% and the Sta PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 months ago

Sector Update: Healthcare Stocks Advance Late Afternoon

Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index adding 0.6% and PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 3 months ago

A Rejected Vote Pushes Capricor (CAPR) Toward A Narrower Path

On August 13, Capricor Therapeutics (NASDAQ:CAPR) held its second-quarter earnings call, just over two weeks after an FDA advisory committee voted 3 to 9 against the company's bid to treat cardiomyopathy in Duchenne muscular dystrophy pati... Full story

Yahoo Finance • 3 months ago

Capricor slips after report on potential Deramiocel rejection

[An arrow pointing downwards on top of a pile of US dollar bills.] Capricor Therapeutics (CAPR [https://seekingalpha.com/symbol/CAPR]) was a notable decliner in biotech on Thursday after a report from STAT News renewed concerns about a po... Full story

Yahoo Finance • 3 months ago

Catalyst Watch: Eyes on Walmart, Alibaba, Reddit, and McDonald's energy drink push

[Stock exchange building columns stock market finance] alexsl Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next we... Full story

Yahoo Finance • 3 months ago

Capricor outlines BLA amendment plan as FDA signals willingness to review, with PDUFA date set for August 22

Earnings Call Insights: Capricor Therapeutics (CAPR) Q2 2026 MANAGEMENT VIEW * Linda Marbán (Co-Founder, President, CEO & Director) said the company’s Deramiocel BLA “remains under review with the FDA with a current PDUFA target action... Full story

Yahoo Finance • 3 months ago

Bronstein, Gewirtz & Grossman LLC Urges Capricor Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

NEW YORK, Aug. 09, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (NASDAQ: CAPR) and... Full story

Yahoo Finance • 3 months ago

Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP Before Application Deadline

SAN FRANCISCO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Hagens Berman encourages investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) who suffered substantial losses to submit your losses now. A securities fraud class action lawsuit has bee... Full story

Yahoo Finance • 3 months ago

Catalyst Watch: Inflation reads, AMAT earnings, Google Pixel event, and MLB on Netflix

[Lower Manhattan Cityscape] Art Wager/E+ via Getty Images Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week.... Full story

Yahoo Finance • 3 months ago

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CAPR

NEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17... Full story

Yahoo Finance • 3 months ago

CAPR Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Capricor Therapeutics, Inc. Securities Lawsuit - Contact The Gross Law Firm

NEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR). Shareholders who purchased shares of CAPR during the class period listed are encou... Full story

Yahoo Finance • 3 months ago

Kaplan Fox Reminds Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors with Significant Losses to Seek a Leadership Role Before Deadline on September 28, 2026

NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) on behalf of investors that pur... Full story

Yahoo Finance • 3 months ago

CAPR Alert: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed, September 28, 2026 Lead Plaintiff Deadline

SAN FRANCISCO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Hagens Berman encourages investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) who suffered substantial losses to submit your losses now. A securities fraud class action lawsuit has bee... Full story

Yahoo Finance • 3 months ago

ROSEN, LEADING INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CAPR

NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17... Full story

Yahoo Finance • 3 months ago

Biotech Stocks Facing FDA Decision In August 2026

(RTTNews) - As we head into August, it's time for our monthly roundup of the upcoming FDA decisions that could move biotech stocks. The August regulatory calendar spans a wide range of indications - from the ultra-rare Fibrodysplasia Ossi... Full story

Yahoo Finance • 3 months ago

Securities Fraud Investigation Into Capricor Therapeutics, Inc. (CAPR) Announced Concerning FDA Review And Advisory Committee Meeting – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

LOS ANGELES, July 31, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Capricor Therapeutics, Inc. (“Capricor”... Full story

Yahoo Finance • 3 months ago

CAPR INVESTOR ALERT: Investigation of Capricor Therapeutics, Inc. Announced by Holzer & Holzer, LLC

ATLANTA, July 30, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) complied with federal securities laws. On July 27, 2026, STATNews reported... Full story